Published in Hepatitis Weekly, March 3rd, 2003
As part of the settlement, Kenilworth, New Jersey-based Schering-Plough will license its U.S. patents for the antiviral drug ribavirin to Three Rivers for royalties on the generic version of the drug.
Three Rivers, based in suburban Pittsburgh, has been battling for 3 years to sell a generic version of ribavirin, which is used in combination with alpha interferon-2b to treat hepatitis C and generated $800 million in sales for Schering-Plough.
Three Rivers still needs approval from the U.S. Food and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.